Modification Agreements in the Biotechnology Industry

119 Contracts & Agreements

Browse by Company

BIOCRYST PHARMACEUTICALS INC (1 contract)
Celldex Therapeutics, Inc. (1)
CHIMERIX INC (2)
CLEVELAND BIOLABS INC (7)
Emergent BioSolutions Inc. (59)
Evelo Biosciences, Inc. (1)
GALECTIN THERAPEUTICS INC (1)
Immunome Inc. (3)
Isoray, Inc. (2)
Medovex Corp. (3)
MiMedx Group, Inc. (1)
NOVAVAX INC (25)
Pfenex Inc. (1)
Protagenic Therapeutics, Inc. (1)
Regeneron Pharmaceuticals (9)
Sarepta Therapeutics, Inc. (2)

Recent Contracts

Modification No. 21 to Undefinitized Project Agreement No. 1, dated February 6, 2024, between the Company and Advanced Technology International (NOVAVAX INC, Filed With SEC on May 10, 2024)
Modification No. 20 to Undefinitized Project Agreement No. 1, dated December 1, 2023, between the Company and Advanced Technology International (NOVAVAX INC, Filed With SEC on May 10, 2024)
Modification No. 19 to Undefinitized Project Agreement No. 1, dated September 19, 2023, between the Company and Advanced Technology International (NOVAVAX INC, Filed With SEC on May 10, 2024)
Modification No. 18 to Undefinitized Project Agreement No. 1, dated May 25, 2023, between the Company and Advanced Technology International (NOVAVAX INC, Filed With SEC on August 8, 2023)
Modification No. 17 to Undefinitized Project Agreement No. 1, dated February 6, 2023, between the Company and Advanced Technology International (NOVAVAX INC, Filed With SEC on May 9, 2023)
Modification of Contract between the Company and the Department of Defense, United States of America, dated January 4, 2023 (Immunome Inc., Filed With SEC on March 16, 2023)
Modification No. 03 to Base Agreement between the Company and Advanced Technology International, dated as of November 30, 2022 (NOVAVAX INC, Filed With SEC on February 28, 2023)
Modification Letter (Evelo Biosciences, Inc., Filed With SEC on November 14, 2022)
Modification No (NOVAVAX INC, Filed With SEC on November 9, 2022)
Modification No (NOVAVAX INC, Filed With SEC on November 9, 2022)
Modification No (NOVAVAX INC, Filed With SEC on November 9, 2022)
Modification No. 02 to Base Agreement between the Company and Advanced Technology International, dated as of August 2, 2022 (NOVAVAX INC, Filed With SEC on November 9, 2022)
Modification No. 06 to Project Agreement, dated as of July 12, 2022, by and between the Registrant and Advanced Technology International (Regeneron Pharmaceuticals, Filed With SEC on November 3, 2022)
Modification No. 04 to Project Agreement, dated as of July 12, 2021, by and between the Registrant and Advanced Technology International (Regeneron Pharmaceuticals, Filed With SEC on November 3, 2022)
Modification No. 03 to Project Agreement, dated as of May 21, 2021, by and between the Registrant and Advanced Technology International (Regeneron Pharmaceuticals, Filed With SEC on November 3, 2022)
Modification No. 02 to Base Agreement, dated as of August 2, 2022, by and between Regeneron Pharmaceuticals, Inc. (the "Registrant") and Advanced Technology International (Regeneron Pharmaceuticals, Filed With SEC on November 3, 2022)
Modification No. 0 (Regeneron Pharmaceuticals, Filed With SEC on August 3, 2022)
Modification No. 29, effective June 16, 2022, to the CDC BioThrax Procurement Contract (Emergent BioSolutions Inc., Filed With SEC on August 2, 2022)
Modification No. 28, effective April 14, 2022, to the CDC BioThrax Procurement Contract (Emergent BioSolutions Inc., Filed With SEC on August 2, 2022)
Modification of Contract between the Company and the Department of Defense, United States of America, dated March 18, 2022 (portions of this exhibit (indicated by asterisks) have... (Immunome Inc., Filed With SEC on May 12, 2022)
Modification No. 01 to Base Agreement between Novavax, Inc. and Advanced Technology International, dated as of March 23, 2022 (NOVAVAX INC, Filed With SEC on May 10, 2022)
Modification No. 5 to Project Agreement, dated as of March 22, 2022, by and between the Registrant and Advanced Technology International (Regeneron Pharmaceuticals, Filed With SEC on May 4, 2022)
Modification No. 1 to Base Agreement, dated as of January 26, 2022, by and between the Registrant and Advanced Technology International (Regeneron Pharmaceuticals, Filed With SEC on May 4, 2022)
Modification No. 27, effective March 31, 2022, to the Solicitation/Contract/Order for Commercial Items (the CDC BioThrax Procurement Contract), effective December 8, 2016, from... (Emergent BioSolutions Inc., Filed With SEC on April 29, 2022)
Modification No. 13 to Undefinitized Project Agreement No. 01, dated February 1, 2022, between the Company and Advanced Technology International (NOVAVAX INC, Filed With SEC on March 1, 2022)
Modification No. 12 to Undefinitized Project Agreement No. 01, dated December 20, 2021, between the Company and Advanced Technology International (NOVAVAX INC, Filed With SEC on March 1, 2022)
Modification No. 32, effective November 1, 2021, to the BARDA ADM Contract (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 31, effective October 20, 2021, to the BARDA ADM Contract (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 8, effective (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 4, effective (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 3, effective (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 6, effective, November 1, 2021 to the ACAM2000 Contract (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 5, effective, September 29, 2021 to the ACAM2000 Contract (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 4, effective, July 13, 2021 to the ACAM2000 Contract (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 1 (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 26, effective November 1, 2021, to the CDC BioThrax Procurement Contract (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 25, effective September 29, 2021, to the CDC BioThrax Procurement Contract (Emergent BioSolutions Inc., Filed With SEC on November 5, 2021)
Modification No. 24, effective February 2, 2021, to the Solicitation/Contract/Order for Commercial Items, effective December 8, 2016, from the Centers for Disease Control and... (Emergent BioSolutions Inc., Filed With SEC on November 5, 2021)
Modification No. 11, effective September 30, 2021, to the BARDA AV7909 Contract (Emergent BioSolutions Inc., Filed With SEC on November 5, 2021)
Modification No. 2, effective August 29, 2018, to the BARDA AV7909 Contract (Emergent BioSolutions Inc., Filed With SEC on November 5, 2021)